Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Methods of Documentation VI: Case Management Model01:15

Methods of Documentation VI: Case Management Model

The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic illness...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Modeling in Therapy01:26

Modeling in Therapy

Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in situations...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.

Advances in therapy·2021
Same author

COVID-19 vaccines and multiple sclerosis disease-modifying therapies.

Multiple sclerosis and related disorders·2021
Same author

Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical·2021
Same author

Evaluation of remote assessments for multiple sclerosis in an in-home setting.

Multiple sclerosis and related disorders·2021
Same author

Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.

Journal of neuroimmunology·2021
Same author

Probing the association between Multiple Sclerosis and Epstein Barr Virus from a therapeutic perspective.

Multiple sclerosis and related disorders·2021
Same journal

Augmentation in Achilles tendon repair: evidence versus enthusiasm.

British medical bulletin·2026
Same journal

Regional musculoskeletal pain in workers-is the traditional medical model increasing disability?

British medical bulletin·2026
Same journal

Human health in relation to visible, functional, and accessible green space: a systematic review and narrative synthesis of the 3 + 30 + 300 guideline.

British medical bulletin·2026
Same journal

Muscle herniae in exercise-induced leg pain: diagnostic pitfalls and the 'repair paradox'.

British medical bulletin·2026
Same journal

Scaffolds and platelet concentrates in bone regenerative medicine: applications, mechanisms, and future approaches.

British medical bulletin·2026
Same journal

Back squat and deadlift fatiguing protocols elicit distinct countermovement jump profiles: phase-specific predictors and soreness responses.

British medical bulletin·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Multiple sclerosis: a practical overview for clinicians.

Konrad Rejdak1, Samuel Jackson, Gavin Giovannoni

  • 1Department of Neurology, Medical University of Lublin, Lublin, Poland.

British Medical Bulletin
|July 7, 2010
PubMed
Summary
This summary is machine-generated.

Multiple sclerosis (MS) is an autoimmune disease in young adults, with new therapies showing promise but carrying risks. Research suggests MS may also be neurodegenerative, requiring neuroprotective treatments to prevent long-term disability.

More Related Videos

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Related Experiment Videos

Last Updated: Jun 11, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Area of Science:

  • Neurology
  • Immunology
  • Neuroimmunology

Background:

  • Multiple sclerosis (MS) is a leading cause of neurological disability in young adults, imposing a significant social burden.
  • Advances in understanding MS pathogenesis and clinical management have shifted focus to multidisciplinary care.
  • Current consensus views MS as an autoimmune disease influenced by environmental factors and genetic susceptibility.

Purpose of the Study:

  • To review recent advances in the understanding and management of multiple sclerosis.
  • To explore emerging concepts regarding MS aetiology, pathogenesis, and potential classification.
  • To highlight the need for neuroprotective therapies in progressive MS.

Main Methods:

  • Literature review utilizing MedLine database.
  • Analysis of recent clinical and pathological insights into MS.
  • Examination of therapeutic responses and emerging biomarkers.

Main Results:

  • First-line disease-modifying therapies reduce relapse rates by approximately one-third.
  • More effective therapies exist but are associated with increased risks.
  • Pathological heterogeneity suggests MS might be a syndrome, with subtypes potentially predicting treatment response.
  • A novel auto-antibody may distinguish neuromyelitis optica from MS.
  • Progressive MS despite immunosuppression suggests a potential neurodegenerative component.

Conclusions:

  • MS management has evolved with new immune interventions, but challenges remain.
  • The aetiology and pathogenesis of MS are complex and may involve both autoimmune and neurodegenerative processes.
  • Personalized medicine approaches, considering pathological subtypes and novel biomarkers, are crucial.
  • Development of neuroprotective therapies is essential to combat progressive disability in MS.